Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Profit After Tax (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Profit After Tax for 10 consecutive years, with -$32.0 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 22.0% to -$32.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.9 million through Dec 2025, up 20.69% year-over-year, with the annual reading at -$49.9 million for FY2025, 20.69% up from the prior year.
  • Profit After Tax for Q4 2025 was -$32.0 million at Rein Therapeutics, down from -$5.6 million in the prior quarter.
  • The five-year high for Profit After Tax was -$1.8 million in Q2 2023, with the low at -$41.0 million in Q4 2024.
  • Average Profit After Tax over 5 years is -$9.1 million, with a median of -$6.8 million recorded in 2021.
  • The sharpest move saw Profit After Tax soared 77.64% in 2023, then plummeted 458.4% in 2024.
  • Over 5 years, Profit After Tax stood at -$6.8 million in 2021, then surged by 33.12% to -$4.5 million in 2022, then plummeted by 61.4% to -$7.3 million in 2023, then tumbled by 458.4% to -$41.0 million in 2024, then rose by 22.0% to -$32.0 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$32.0 million, -$5.6 million, and -$6.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.